Small pouches, but high nicotine doses-nicotine delivery and acute effects after use of tobacco-free nicotine pouches.

arterial stiffness cardiovascular effects craving reduction high nicotine doses nicotine delivery nicotine pouches pharmacokinetics

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 26 02 2024
accepted: 22 04 2024
medline: 6 6 2024
pubmed: 6 6 2024
entrez: 6 6 2024
Statut: epublish

Résumé

Tobacco-free nicotine pouches are new nicotine products for oral consumption. They can contain very high nicotine amounts that have not been addressed with clinical studies yet. Thus, nicotine delivery, effects on craving, and side effects were assessed using pouches with up to 30 mg nicotine. In this single-center, five-arm, crossover study, 15 regular cigarette smokers consumed tobacco-free nicotine pouches from different brands with 6, 20, and 30 mg for 20 min. Comparators were nicotine-free pouches and tobacco cigarettes. At baseline and predefined time points over a study period of 240 min, plasma nicotine concentrations, effects on cigarette craving, and side effects were assessed. Cardiovascular parameters including arterial stiffness were measured using a MobilOGraph. Consumption of 30 mg nicotine pouches has led to a higher nicotine uptake compared with the cigarette (C

Identifiants

pubmed: 38841367
doi: 10.3389/fphar.2024.1392027
pii: 1392027
pmc: PMC11150668
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1392027

Informations de copyright

Copyright © 2024 Mallock-Ohnesorg, Rabenstein, Stoll, Gertzen, Rieder, Malke, Burgmann, Laux, Pieper, Schulz, Franzen, Luch and Rüther.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Nadja Mallock-Ohnesorg (N)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Institute of Legal Medicine, Goethe-University Frankfurt, Frankfurt/Main, Germany.

Andrea Rabenstein (A)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Yvonne Stoll (Y)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Marcus Gertzen (M)

Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

Benedikt Rieder (B)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Sebastian Malke (S)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Nestor Burgmann (N)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Peter Laux (P)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Elke Pieper (E)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Thomas Schulz (T)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Klaas Franzen (K)

Medical Clinic III, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany.
Airway Research Center North, Member of the German Center for Lung Research (DZL), Großhansdorf, Germany.

Andreas Luch (A)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Tobias Rüther (T)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Classifications MeSH